Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
INTUITIVE SURGICAL INC executive Jamie Samath, EVP & CFO & Enterprise Technol, reported equity award activity involving performance and restricted stock units. On February 28, 2026, 10,773 performance stock units and 752 restricted stock units were converted into common stock following achievement of performance criteria and scheduled vesting. To satisfy statutory tax withholding obligations tied to these vestings, 373 and 5,343 common shares, respectively, were withheld at a price of $503.51 per share, with the remaining net shares delivered into the holder’s account.
Intuitive Surgical executive Gary Loeb exercised performance stock units and had shares withheld for taxes. On February 28, 2026, he converted 3,148 performance stock units granted on February 28, 2023 into 3,148 shares of common stock at $0.0000 per share, following achievement of required performance criteria.
The performance stock units vest on February 28, 2026, the third anniversary of the grant date, subject to his continuous service. In connection with this settlement, 1,562 common shares were withheld at $503.5100 per share to cover applicable taxes, leaving him with 6,520 directly owned common shares.
Intuitive Surgical EVP Henry L. Charlton reported multiple equity award settlements in the form of stock unit conversions and tax withholdings. On February 28, 2026, 10,773 performance stock units and 752 restricted stock units converted into common stock at no exercise price. A total of 335 and 4,800 common shares were withheld at $503.51 per share to cover statutory tax obligations related to these vestings. RSUs vest 25% per year over four years, while the reported PSUs vest on February 28, 2026 after performance criteria were achieved. Following these transactions, Charlton directly owned 11,610 shares of common stock.
Intuitive Surgical, Inc. has completed its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates. This move shifts Intuitive to direct commercial operations in Italy, Spain, Portugal, Malta, San Marino, and associated territories.
The acquired business is now wholly owned and integrated into Intuitive’s European commercial and marketing organization, led by Senior Vice President and General Manager Dirk Barten. Approximately 250 employees are joining Intuitive as part of this expansion.
There were more than 470 da Vinci surgical systems installed in Italy, Spain, and Portugal as of December 31, 2025, providing an established base for Intuitive’s expanded direct presence in minimally invasive and robotic-assisted surgery in Southern Europe.
Intuitive Surgical CEO David J. Rosa reported multiple equity transactions on February 28, 2026 tied to vesting of performance and restricted stock units. He exercised or converted derivative awards into common stock, including 14,363 and 9,052 performance stock units from 2023 grants and 1,503 restricted stock units, each on a one-for-one basis into common shares.
To satisfy statutory tax withholding on these settlements, the company withheld shares classified as dispositions under code F, including 7,122, 4,489, and 746 common shares at a price of $503.51 per share. After these exercises and tax-withholding dispositions, Rosa directly owned 245,209 shares of Intuitive Surgical common stock.
Intuitive Surgical SVP and Chief Manufacturing and Supply Chain Officer Mark Brosius reported equity vesting and related tax withholdings. On February 28, 2026, 8,378 performance stock units granted on February 28, 2023 and 877 restricted stock units granted on February 28, 2022 converted into common stock.
In connection with these settlements, 435 and 4,155 shares of common stock were withheld at a price of $503.51 per share to cover tax liabilities and exercise costs. After these transactions, Brosius directly owned 6,564 shares of Intuitive Surgical common stock.
Myriam Curet McAdams filed a Form 144 reporting proposed and recent sales of Common stock of ISRG. The filing shows a proposed sale of 125 shares via a stock option exercise on 03/02/2026 for cash.
The filing also lists several sales by the same holder in the prior three months, including 2,345 shares on 02/27/2026 (1171819.95), 421 shares on 02/11/2026 (208378.16), and 105 shares on 02/10/2026 (51938.25).
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported multiple equity award transactions involving performance stock units (PSUs), restricted stock units (RSUs), and common stock. PSUs initially granted on February 28, 2023 had their performance criteria certified, and the resulting PSUs vested on February 28, 2026, converting into common shares.
On the same date, RSUs also vested and converted one-for-one into common stock. Some of the newly delivered shares were withheld to cover statutory tax obligations related to the PSU and RSU settlements, using shares valued at about $503.51 per share. In a separate move on February 27, 2026, a trust associated with Curet sold 2,345 shares of Intuitive Surgical common stock at an average price of $499.71 per share under a pre-arranged Rule 10b5-1 trading plan that expires on July 29, 2026.
Intuitive Surgical senior executive Patricia L. Wadors reported mixed equity transactions. She sold 220 shares of common stock in an open-market sale at $499.71 per share under a Rule 10b5-1 trading plan that expires on June 5, 2026. In connection with RSUs vesting, 458 shares were delivered, with 238 shares withheld at $506.17 per share to cover taxes. She also received a new grant of 3,584 restricted stock units that vest 25% annually over four years, each RSU representing one share of common stock upon vesting.
Fredrik Widman reported a Form 144 sale notice for 133 common shares of ISRG sold on 02/11/2026 for $65,829.68.
The filing lists restricted stock activity and a separate entry showing 249 units dated 02/26/2026; the primary disclosed sale was the 133-share transaction.